A two-month administration of genistein increases the oxidative capacity of fatty acids in the skeletal muscle, thus improving insulin sensitivity in subjects with metabolic syndrome that was associated with a modification of the microbiome composition (particularly an increase in Akkermansia muciniphila content) [78]. The gene discussed is INS; the disease is metabolic syndrome.